Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema.
Dexamethasone implant
Diabetic macular edema
Subtenon triamcinolone acetonide
Switch
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
received:
14
10
2023
accepted:
12
04
2024
revised:
18
03
2024
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
aheadofprint
Résumé
Intraocular dexamethasone implant (DEXi) is an efficient treatment for diabetic macular edema (DME). However, it may be unavailable or contraindicated. Triamcinolone acetonide is another corticosteroid that has proved to be safe and effective in treating macular edema complicating various diseases including diabetes. The purpose of this study is to evaluate the outcomes of a switch from DEXi to subtenon triamcinolone acetonide (STTA) and back, in eyes with DME. Retrospective study. DME eyes that had been treated with DEXi and switched to STTA between October 2018 and February 2019 (stock shortage of DEXi) were included. The functional and anatomical outcomes of the switch and switch-back were studied. 26 eyes of 17 patients (mean age 67.1 ± 8.2 years) were considered. The mean baseline visual acuity (VA) was 0.35 ± 0.17 decimals remaining stable after DEXi, STTA and switch-back to DEXi. The mean central macular thickness (CMT) was 492.7 ± 32.8 µm initially, decreasing to 294.3 ± 133.4 µm after DEXi, 369.9 ± 182.3 µm after STTA and 297.6 ± 72.0 µm after switching back to DEXi (all p < 0.05 versus baseline). Compared to baseline, the CMT reduction was numerically better after DEXi and switching back to DEXi than after STTA (mean reduction: -200.4 µm, -167.7 µm, and -95.08 µm respectively, p = 0.13). Intraocular pressure was comparable after DEXi and STTA. DEXi is the steroid of choice in DME. However, STTA can be a cost-effective alternative when DEXi is unavailable or contraindicated. This study suggests that STTA may be used in the context of a step therapy in DME.
Sections du résumé
BACKGROUND
BACKGROUND
Intraocular dexamethasone implant (DEXi) is an efficient treatment for diabetic macular edema (DME). However, it may be unavailable or contraindicated. Triamcinolone acetonide is another corticosteroid that has proved to be safe and effective in treating macular edema complicating various diseases including diabetes. The purpose of this study is to evaluate the outcomes of a switch from DEXi to subtenon triamcinolone acetonide (STTA) and back, in eyes with DME.
METHODS
METHODS
Retrospective study. DME eyes that had been treated with DEXi and switched to STTA between October 2018 and February 2019 (stock shortage of DEXi) were included. The functional and anatomical outcomes of the switch and switch-back were studied.
RESULTS
RESULTS
26 eyes of 17 patients (mean age 67.1 ± 8.2 years) were considered. The mean baseline visual acuity (VA) was 0.35 ± 0.17 decimals remaining stable after DEXi, STTA and switch-back to DEXi. The mean central macular thickness (CMT) was 492.7 ± 32.8 µm initially, decreasing to 294.3 ± 133.4 µm after DEXi, 369.9 ± 182.3 µm after STTA and 297.6 ± 72.0 µm after switching back to DEXi (all p < 0.05 versus baseline). Compared to baseline, the CMT reduction was numerically better after DEXi and switching back to DEXi than after STTA (mean reduction: -200.4 µm, -167.7 µm, and -95.08 µm respectively, p = 0.13). Intraocular pressure was comparable after DEXi and STTA.
CONCLUSION
CONCLUSIONS
DEXi is the steroid of choice in DME. However, STTA can be a cost-effective alternative when DEXi is unavailable or contraindicated. This study suggests that STTA may be used in the context of a step therapy in DME.
Identifiants
pubmed: 38668853
doi: 10.1007/s00417-024-06492-z
pii: 10.1007/s00417-024-06492-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232. https://doi.org/10.3109/08820539909069541
doi: 10.3109/08820539909069541
pubmed: 10758223
Bressler NM, Beaulieu WT, Maguire MG et al (2018) Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T. Am J Ophthalmol 195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030
doi: 10.1016/j.ajo.2018.07.030
pubmed: 30077569
pmcid: 6648655
Munk MR, Somfai GM, de Smet MD et al (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. Int J Mol Sci 23:7585. https://doi.org/10.3390/ijms23147585
doi: 10.3390/ijms23147585
pubmed: 35886930
pmcid: 9319632
Vujosevic S, Toma C, Villani E et al (2020) Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. Acta Diabetol 57:287–296. https://doi.org/10.1007/s00592-019-01424-4
doi: 10.1007/s00592-019-01424-4
pubmed: 31541333
Zhang J, Zhang J, Zhang C et al (2022) Diabetic Macular Edema: Current Understanding. Mol Mech Therapeutic Implications Cells 11:3362. https://doi.org/10.3390/cells11213362
doi: 10.3390/cells11213362
Maturi RK, Glassman AR, Liu D et al (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 136:29–38. https://doi.org/10.1001/jamaophthalmol.2017.4914
doi: 10.1001/jamaophthalmol.2017.4914
pubmed: 29127949
Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C et al (2019) Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15. https://doi.org/10.1186/s12886-018-1022-9
doi: 10.1186/s12886-018-1022-9
pubmed: 30634940
pmcid: 6330395
Boyer DS, Yoon YH, Belfort R et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024
doi: 10.1016/j.ophtha.2014.04.024
pubmed: 24907062
Patil NS, Mihalache A, Hatamnejad A et al (2023) Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: A Meta-Analysis. Ophthalmol Retina 7:289–299. https://doi.org/10.1016/j.oret.2022.10.008
doi: 10.1016/j.oret.2022.10.008
pubmed: 36272716
Jhaveri CD, Glassman AR, Ferris FL et al (2022) Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med 387:692–703. https://doi.org/10.1056/NEJMoa2204225
doi: 10.1056/NEJMoa2204225
pubmed: 35833805
pmcid: 9714135
Erden B, Çakır A, Aslan AC et al (2019) The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome. Ocul Immunol Inflamm 27:1235–1241. https://doi.org/10.1080/09273948.2019.1620786
doi: 10.1080/09273948.2019.1620786
pubmed: 31411519
Choopong P, Taetrongchit N, Boonsopon S et al (2022) Efficacy of subtenon 20-mg triamcinolone injection versus 0.1% dexamethasone eye drops for controlling inflammation after phacoemulsification: a randomized controlled trial. Sci Rep 12:16471. https://doi.org/10.1038/s41598-022-20522-y
doi: 10.1038/s41598-022-20522-y
pubmed: 36183042
pmcid: 9526735
Ozkurt YB, Akkaya S, Aksoy S et al (2015) Posterior Subtenon’s Capsule Triamcinolone Acetonide Injection for the Treatment of Diabetic Macular Edema. J Ocul Pharmacol Ther 31:455–460. https://doi.org/10.1089/jop.2014.0130
doi: 10.1089/jop.2014.0130
pubmed: 26154736
Jung JL, Harasawa M, Patnaik JL, Palestine AG (2022) Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis. Ophthalmol Ther 11:811–820. https://doi.org/10.1007/s40123-022-00480-4
doi: 10.1007/s40123-022-00480-4
pubmed: 35179713
pmcid: 8927513
Erdogan G, Gumus G, Gunay BO, Ozkaya A (2023) Posterior sub-Tenon triamcinolone injection in the treatment of postoperative cystoid macular edema secondary to pars plana vitrectomy. Indian J Ophthalmol 71:174–179. https://doi.org/10.4103/ijo.IJO_621_22
doi: 10.4103/ijo.IJO_621_22
pubmed: 36588230
Carbonnière C, Couret C, Blériot A et al (2017) Treatment of macular edema: Comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon’s triamcinolone injections and intravitreal dexamethasone implant. J Fr Ophtalmol 40:177–186. https://doi.org/10.1016/j.jfo.2016.11.013
doi: 10.1016/j.jfo.2016.11.013
pubmed: 28318718
Thorne JE, Sugar EA, Holbrook JT et al (2019) Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology 126:283–295. https://doi.org/10.1016/j.ophtha.2018.08.021
doi: 10.1016/j.ophtha.2018.08.021
pubmed: 30269924
Gumus G, Erdogan G, Gunay BO, Karatas Durusoy G (2022) Comparison of Intravitreal Dexamethasone Implant and Posterior Subtenon Triamcinolone Injection in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. Ophthalmologica 245:439–445. https://doi.org/10.1159/000526172
doi: 10.1159/000526172
pubmed: 35921811
He Y, Ren X-J, Hu B-J et al (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18:121. https://doi.org/10.1186/s12886-018-0779-1
doi: 10.1186/s12886-018-0779-1
pubmed: 29784048
pmcid: 5963018
Ehlers JP, Yeh S, Maguire MG et al (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology 129:88–99. https://doi.org/10.1016/j.ophtha.2021.07.009
doi: 10.1016/j.ophtha.2021.07.009
pubmed: 34446301
Bux AV, Fortunato F, Barone A et al (2022) Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients. Eur J Ophthalmol 32:1619–1626. https://doi.org/10.1177/11206721211024804
doi: 10.1177/11206721211024804
pubmed: 34120496
Callanan DG, Loewenstein A, Patel SS et al (2017) A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:463–473. https://doi.org/10.1007/s00417-016-3472-1
doi: 10.1007/s00417-016-3472-1
pubmed: 27632215
Cellini M, Pazzaglia A, Zamparini E et al (2008) Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol 8:5. https://doi.org/10.1186/1471-2415-8-5
doi: 10.1186/1471-2415-8-5
pubmed: 18366650
pmcid: 2277375
Choi YJ, Oh IK, Oh JR, Huh K (2006) Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol 20:205–209. https://doi.org/10.3341/kjo.2006.20.4.205
doi: 10.3341/kjo.2006.20.4.205
pubmed: 17302204
pmcid: 2908852
Kurt MM, Çekiç O, Akpolat Ç et al (2017) Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema. Eye (Lond) 31:1155–1162. https://doi.org/10.1038/eye.2017.46
doi: 10.1038/eye.2017.46
pubmed: 28338665
Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294. https://doi.org/10.1016/j.ajo.2004.09.038
doi: 10.1016/j.ajo.2004.09.038
pubmed: 15733990
Kim MW, Moon H, Yang SJ, Joe SG (2016) Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J Ophthalmol 30:25–31. https://doi.org/10.3341/kjo.2016.30.1.25
doi: 10.3341/kjo.2016.30.1.25
pubmed: 26865800
pmcid: 4742642
Liu B, Ma G, Hou J, Cong C (2022) Choroidal Structural Changes of Posterior Subtenon Triamcinolone Acetonide Injection in Eyes with Refractory Diabetic Macular Edema. J Ophthalmol 2022:6882607. https://doi.org/10.1155/2022/6882607
doi: 10.1155/2022/6882607
pubmed: 35237449
pmcid: 8885276
Shimura M, Yasuda K, Minezaki T, Noma H (2016) Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 60:401–407. https://doi.org/10.1007/s10384-016-0458-9
doi: 10.1007/s10384-016-0458-9
pubmed: 27306783
Inoue M, Takeda K, Morita K et al (2004) Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 138:1046–1048. https://doi.org/10.1016/j.ajo.2004.05.028
doi: 10.1016/j.ajo.2004.05.028
pubmed: 15629301
Ogura Y, Shimura M, Iida T et al (2019) Phase II/III Clinical Trial of Sub-Tenon Injection of Triamcinolone Acetonide (WP-0508ST) for Diabetic Macular Edema. Ophthalmologica 241:161–169. https://doi.org/10.1159/000492135
doi: 10.1159/000492135
pubmed: 30176671
Rosenblatt A, Udaondo P, Cunha-Vaz J et al (2020) A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: The European DME Registry Study. Ophthalmology 127:377–393. https://doi.org/10.1016/j.ophtha.2019.10.005
doi: 10.1016/j.ophtha.2019.10.005
pubmed: 31932090
Dutra Medeiros M, Alkabes M, Nucci P (2014) Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. Eur Endocrinol 10:111–116. https://doi.org/10.17925/EE.2014.10.02.111
doi: 10.17925/EE.2014.10.02.111
pubmed: 29872474
pmcid: 5983079
Xia H-H, Chen J-L, Chen H-Y, Lin H-J (2020) Correlation between optical coherence tomography, multifocal electroretinogram findings and visual acuity in diabetic macular edema. Int J Ophthalmol 13:1592–1596. https://doi.org/10.18240/ijo.2020.10.13
doi: 10.18240/ijo.2020.10.13
pubmed: 33078110
pmcid: 7511372
Shen Y, Liu K, Xu X (2016) Correlation Between Visual Function and Photoreceptor Integrity in Diabetic Macular Edema: Spectral-Domain Optical Coherence Tomography. Curr Eye Res 41:391–399. https://doi.org/10.3109/02713683.2015.1019003
doi: 10.3109/02713683.2015.1019003
pubmed: 25897822
Abd Elhamid AH (2019) Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema. J Ophthalmol 2019:8216150. https://doi.org/10.1155/2019/8216150
doi: 10.1155/2019/8216150
pubmed: 30906587
pmcid: 6397985
Toda J, Fukushima H, Kato S (2009) Systemic complications of posterior subtenon injection of triamcinolone acetonide in type 2 diabetes patients. Diabetes Res Clin Pract 84:e38-40. https://doi.org/10.1016/j.diabres.2008.10.020
doi: 10.1016/j.diabres.2008.10.020
pubmed: 19233498
Kaderli B, Kivanc SA, Inan UU et al (2014) Effect of posterior subtenon injection of 40 mg of triamcinolone acetonide on glycemic control and serum cortisol and adrenocorticotropic hormone in diabetic patients. Eur Rev Med Pharmacol Sci 18:2609–2614
pubmed: 25317793
Karti O, Saatci AO (2021) Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes 12:1220–1232. https://doi.org/10.4239/wjd.v12.i8.1220
doi: 10.4239/wjd.v12.i8.1220
pubmed: 34512888
pmcid: 8394236
Mehta H, Hennings C, Gillies MC et al (2018) Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev 4:CD01599. https://doi.org/10.1002/14651858.CD011599.pub2
doi: 10.1002/14651858.CD011599.pub2
Yang Y-H, Kuo H-H, Hsu W-C, Hsieh Y-T (2020) Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases. Int J Ophthalmol 13:946–951. https://doi.org/10.18240/ijo.2020.06.14
doi: 10.18240/ijo.2020.06.14
pubmed: 32566507
pmcid: 7270252
Base de données publique des médicaments. https://base-donnees-publique.medicaments.gouv.fr/
Tripathy K (2023) Commentary: Posterior subtenon triamcinolone - The unsung hero for managing various ocular disorders. Indian J Ophthalmol 71:181–182. https://doi.org/10.4103/ijo.IJO_1963_22
doi: 10.4103/ijo.IJO_1963_22
pubmed: 36588232
pmcid: 10155584